Well-defined examples of the ML approach in the analysis of hematological malignancies are the association of BCL6 and PDL1/2 rearrangements in primary testicular diffuse large B-cell lymphoma (DLBCL) with central nervous system relapse (51); the involvement of six prognosis-related long non-coding genes in acute myeloid leukemia (AML) patients (52); or the relevance of tumor mutation burden for the DLBCL overall survival prognostication (53) are. This evidence concerns the gene BCL6 and acute myeloid leukemia.